Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
28/09/2022 12:09
Sept 28 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON PHASE 3 CLINICAL
TRIAL
FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS - FDA PROVIDED COMMUNICATION THAT
AMENDED
PROTOCOL IS STILL UNDER REVIEW AND CURRENTLY DOES NOT SUPPORT
REVISED PRIMARY ENDPOINT
* REVIVE THERAPEUTICS - FDA ADVISED CO TO SUBMIT A MEETING
REQUEST
TO DISCUSS APPROPRIATE ENDPOINTS, JUSTIFICATION OF RELEVANCE OF
REVISED PRIMARY ENDPOINT
* REVIVE THERAPEUTICS LTD - COMPANY WOULD PROCEED TO SEEK A
MEETING WITH FDA TO AGREE ON A PROPOSED PLAN FOR POTENTIAL
REGULATORY APPROVAL
Source text for Eikon: ID:nGNX3G0Vqh
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure